{"pmid":32365275,"title":"Obesity accompanying COVID-19: the role of epicardial fat.","text":["Obesity accompanying COVID-19: the role of epicardial fat.","With interest we read the study by Simonnet A et al. (1) in which important novel evidence is addressed that obesity is highly frequent among critically ill patients with severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) infection. Although clinically very relevant, it remains difficult to elucidate the mechanisms by which SARS-Cov-2 severity is increased in the context of obesity. As reported by Katz JN et al. (2), 28% of hospitalised patients with coronavirus disease 2019 (COVID-19) presented cardiac complications including myocarditis, arrhythmias, heart failure (HF) and sudden death. Considering that myocardial response in COVID-19 is closely associated with in-hospital mortality, local biological effects on myocardial tissue from epicardial adipose tissue (EAT) is warrant further discussion.","Obesity (Silver Spring)","Zhao, Lei","32365275"],"abstract":["With interest we read the study by Simonnet A et al. (1) in which important novel evidence is addressed that obesity is highly frequent among critically ill patients with severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) infection. Although clinically very relevant, it remains difficult to elucidate the mechanisms by which SARS-Cov-2 severity is increased in the context of obesity. As reported by Katz JN et al. (2), 28% of hospitalised patients with coronavirus disease 2019 (COVID-19) presented cardiac complications including myocarditis, arrhythmias, heart failure (HF) and sudden death. Considering that myocardial response in COVID-19 is closely associated with in-hospital mortality, local biological effects on myocardial tissue from epicardial adipose tissue (EAT) is warrant further discussion."],"journal":"Obesity (Silver Spring)","authors":["Zhao, Lei"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32365275","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/oby.22867","topics":["Treatment"],"weight":1,"_version_":1666138495975948290,"score":9.490897,"similar":[{"pmid":32314861,"title":"Obesity is associated with severe forms of COVID-19.","text":["Obesity is associated with severe forms of COVID-19.","We have read with great interest the Brief Cutting Edge Report from Simonnet et al. which reports a high prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) requiring invasive mechanical ventilation. In the context of unprecedented health crisis due to the coronavirus disease 2019 (COVID-19) outbreak, these results are of a great importance and may have major implications in public health strategy especially in western countries affected by a high prevalence of obesity.","Obesity (Silver Spring)","Caussy, Cyrielle","Wallet, Florent","Laville, Martine","Disse, Emmanuel","32314861"],"abstract":["We have read with great interest the Brief Cutting Edge Report from Simonnet et al. which reports a high prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) requiring invasive mechanical ventilation. In the context of unprecedented health crisis due to the coronavirus disease 2019 (COVID-19) outbreak, these results are of a great importance and may have major implications in public health strategy especially in western countries affected by a high prevalence of obesity."],"journal":"Obesity (Silver Spring)","authors":["Caussy, Cyrielle","Wallet, Florent","Laville, Martine","Disse, Emmanuel"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314861","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/oby.22842","topics":["Treatment"],"weight":1,"_version_":1666138493433151488,"score":182.7021},{"pmid":32492562,"title":"The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.","text":["The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.","It is widely believed that infection with the SARS-CoV-2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease. Immune cells accumulate in visceral adipose tissue and together with paracrine adipocytes release a wide range of biologically active cytokines (including IL-1beta, IL5, IL6 and IL8) that can result in both local, pulmonary and systemic inflammation. A more intense 'cytokine storm' is postulated as the mechanism behind the extreme immune response seen in severe COVID-19. It is striking how dangerous the combination of obesity and COVID-19 is, resulting in a greater risk of ICU admission and a higher mortality. Furthermore, patients from a BAME background appear to have increased mortality after SARS-CoV-2 infection; they also have a higher prevalence of central obesity and its metabolic complications. In the absence of an effective vaccine, the therapeutic potential of immune-modulating drugs is a priority, but the development of new drugs is expensive and time-consuming. A more pragmatic solution would be to seek to repurpose existing drugs, particularly those that might suppress the heightened cytokine activity seen in obesity, the major risk factor for a poor prognosis in COVID-19. Montelukast is a cysteinyl leukotriene receptor antagonist licensed to treat asthma and allergic rhinitis. It has been shown to diminish pulmonary response to antigen, tissue eosinophilia and IL-5 expression in inflammatory cells. It has also been shown to decrease elevated levels of IL-1beta and IL8 in humans with viral upper respiratory tract infections compared with placebo-treated patients. In addition, in silico studies have demonstrated a high binding affinity of the montelukast molecule to the terminal site of the virus's main protease enzyme which is needed for virus RNA synthesis and replication. Montelukast, which is cheap, safe and widely available would appear to have the potential to be an ideal candidate drug for clinical trials, particularly in early stage disease before irreparable tissue damage has already occurred. HYPOTHESIS: Through a direct anti-viral effect, or by suppression of heightened cytokine release in response to SARS-CoV-2, montelukast will reduce the severity of immune-mediated multiorgan damage resulting from COVID-19, particularly in patients with central obesity and metabolic syndrome.","Med Hypotheses","Almerie, Muhammad Qutayba","Kerrigan, David Daniel","32492562"],"abstract":["It is widely believed that infection with the SARS-CoV-2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease. Immune cells accumulate in visceral adipose tissue and together with paracrine adipocytes release a wide range of biologically active cytokines (including IL-1beta, IL5, IL6 and IL8) that can result in both local, pulmonary and systemic inflammation. A more intense 'cytokine storm' is postulated as the mechanism behind the extreme immune response seen in severe COVID-19. It is striking how dangerous the combination of obesity and COVID-19 is, resulting in a greater risk of ICU admission and a higher mortality. Furthermore, patients from a BAME background appear to have increased mortality after SARS-CoV-2 infection; they also have a higher prevalence of central obesity and its metabolic complications. In the absence of an effective vaccine, the therapeutic potential of immune-modulating drugs is a priority, but the development of new drugs is expensive and time-consuming. A more pragmatic solution would be to seek to repurpose existing drugs, particularly those that might suppress the heightened cytokine activity seen in obesity, the major risk factor for a poor prognosis in COVID-19. Montelukast is a cysteinyl leukotriene receptor antagonist licensed to treat asthma and allergic rhinitis. It has been shown to diminish pulmonary response to antigen, tissue eosinophilia and IL-5 expression in inflammatory cells. It has also been shown to decrease elevated levels of IL-1beta and IL8 in humans with viral upper respiratory tract infections compared with placebo-treated patients. In addition, in silico studies have demonstrated a high binding affinity of the montelukast molecule to the terminal site of the virus's main protease enzyme which is needed for virus RNA synthesis and replication. Montelukast, which is cheap, safe and widely available would appear to have the potential to be an ideal candidate drug for clinical trials, particularly in early stage disease before irreparable tissue damage has already occurred. HYPOTHESIS: Through a direct anti-viral effect, or by suppression of heightened cytokine release in response to SARS-CoV-2, montelukast will reduce the severity of immune-mediated multiorgan damage resulting from COVID-19, particularly in patients with central obesity and metabolic syndrome."],"journal":"Med Hypotheses","authors":["Almerie, Muhammad Qutayba","Kerrigan, David Daniel"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492562","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109883","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433510944768,"score":153.50093},{"pmid":32397007,"title":"There is a relationship between obesity and COVID-19 but more information is needed.","text":["There is a relationship between obesity and COVID-19 but more information is needed.","We read with particular interest your comments in Obesity regarding the Coronavirus-19 (COVID-19) epidemic (1) and a related manuscript by Simonnet et al. (2). Resolution of the specific relationship between obesity and COVID-19, two existing public health epidemics, is critically needed to potentially prevent health systems worldwide from being overburdened. Few studies describing COVID-19 with rates of obesity exist, and most are based on heterogeneous populations (Table 1) (2-7). In cohort studies with COVID-19 disease, obesity rates are generally reported as no higher than population-based estimates; in contrast, subgroups of critically ill patients (e.g, intensive care unit (ICU)) report higher prevalence rates of obesity.","Obesity (Silver Spring)","Buscemi, Silvio","Buscemi, Carola","Batsis, John A","32397007"],"abstract":["We read with particular interest your comments in Obesity regarding the Coronavirus-19 (COVID-19) epidemic (1) and a related manuscript by Simonnet et al. (2). Resolution of the specific relationship between obesity and COVID-19, two existing public health epidemics, is critically needed to potentially prevent health systems worldwide from being overburdened. Few studies describing COVID-19 with rates of obesity exist, and most are based on heterogeneous populations (Table 1) (2-7). In cohort studies with COVID-19 disease, obesity rates are generally reported as no higher than population-based estimates; in contrast, subgroups of critically ill patients (e.g, intensive care unit (ICU)) report higher prevalence rates of obesity."],"journal":"Obesity (Silver Spring)","authors":["Buscemi, Silvio","Buscemi, Carola","Batsis, John A"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32397007","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/oby.22883","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666627827884097538,"score":149.15964},{"pmid":32500721,"title":"Approach to Acute Cardiovascular Complications in COVID-19 Infection.","text":["Approach to Acute Cardiovascular Complications in COVID-19 Infection.","The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic. It has spread to more than 187 countries with a rapidly growing number of affected patients. Underlying cardiovascular disease is associated with more severe manifestations of COVID-19 and higher rates of mortality. COVID-19 can have both primary (arrhythmias, myocardial infarction, myocarditis) and secondary (myocardial injury/biomarker elevation, heart failure) cardiac involvement. In severe cases, profound circulatory failure can result. This review discusses the presentation and management of patients with severe cardiac complications of COVID-19 disease, with an emphasis on a \"Heart-Lung\" team approach in patient management. Furthermore, it focuses on the use of and indications for acute mechanical circulatory support in cardiogenic and/or mixed shock.","Circ Heart Fail","Ranard, Lauren S","Fried, Justin A","Abdalla, Marwah","Anstey, D Edmund","Givens, Raymond C","Kumaraiah, Deepa","Kodali, Susheel K","Takeda, Koji","Karmpaliotis, Dimitri","Rabbani, LeRoy E","Sayer, Gabriel","Kirtane, Ajay J","Leon, Martin B","Schwartz, Allan","Uriel, Nir","Masoumi, Amirali","32500721"],"abstract":["The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic. It has spread to more than 187 countries with a rapidly growing number of affected patients. Underlying cardiovascular disease is associated with more severe manifestations of COVID-19 and higher rates of mortality. COVID-19 can have both primary (arrhythmias, myocardial infarction, myocarditis) and secondary (myocardial injury/biomarker elevation, heart failure) cardiac involvement. In severe cases, profound circulatory failure can result. This review discusses the presentation and management of patients with severe cardiac complications of COVID-19 disease, with an emphasis on a \"Heart-Lung\" team approach in patient management. Furthermore, it focuses on the use of and indications for acute mechanical circulatory support in cardiogenic and/or mixed shock."],"journal":"Circ Heart Fail","authors":["Ranard, Lauren S","Fried, Justin A","Abdalla, Marwah","Anstey, D Edmund","Givens, Raymond C","Kumaraiah, Deepa","Kodali, Susheel K","Takeda, Koji","Karmpaliotis, Dimitri","Rabbani, LeRoy E","Sayer, Gabriel","Kirtane, Ajay J","Leon, Martin B","Schwartz, Allan","Uriel, Nir","Masoumi, Amirali"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500721","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1161/CIRCHEARTFAILURE.120.007220","keywords":["covid-19"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668890966290857984,"score":147.85495},{"pmid":32387864,"title":"SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects.","text":["SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects.","BACKROUND AND AIMS: According to the World Obesity Federation, \"obesity-related conditions seem to worsen the effect of Covid-19 (SARS-CoV-2)\"; additionally the Centres for Disease Control and Prevention reported that \"people with heart disease and diabetes are at higher risk of SARS-CoV-2 complications and that severe obesity poses a higher risk for severe illness\". Recent reports have shown elevated levels of cytokines due to increased inflammation in patients with SARS-CoV-2 disease. On the other hand, obesity represents a state of low-grade inflammation, with various inflammatory products directly excreted by adipose tissue. In this concise report we aimed to assess common elements of obesity and SARS-CoV-2 infection. METHODS: Pubmed search on obesity and SARS-CoV-2 infection. RESULTS: We present \"mechanistic\" obesity-related problems that aggravate SARS-CoV-2 infection as well as tentative inflammatory/metabolic links between these diseases. CONCLUSION: Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese.","Diabetes Metab Syndr","Michalakis, Konstantinos","Ilias, Ioannis","32387864"],"abstract":["BACKROUND AND AIMS: According to the World Obesity Federation, \"obesity-related conditions seem to worsen the effect of Covid-19 (SARS-CoV-2)\"; additionally the Centres for Disease Control and Prevention reported that \"people with heart disease and diabetes are at higher risk of SARS-CoV-2 complications and that severe obesity poses a higher risk for severe illness\". Recent reports have shown elevated levels of cytokines due to increased inflammation in patients with SARS-CoV-2 disease. On the other hand, obesity represents a state of low-grade inflammation, with various inflammatory products directly excreted by adipose tissue. In this concise report we aimed to assess common elements of obesity and SARS-CoV-2 infection. METHODS: Pubmed search on obesity and SARS-CoV-2 infection. RESULTS: We present \"mechanistic\" obesity-related problems that aggravate SARS-CoV-2 infection as well as tentative inflammatory/metabolic links between these diseases. CONCLUSION: Obesity and SARS-CoV-2 share common elements of the inflammatory process (and possibly also metabolic disturbances), exacerbating SARS-CoV-2 infection in the obese."],"journal":"Diabetes Metab Syndr","authors":["Michalakis, Konstantinos","Ilias, Ioannis"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387864","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.dsx.2020.04.033","keywords":["coronavirus","glucose","human","infection","inflammation","obesity"],"locations":["obese"],"topics":["Mechanism"],"weight":1,"_version_":1666428892678717440,"score":147.00227}]}